A new analysis from the landmark RxPONDER clinical trial reveals that measuring anti-Müllerian hormone (AMH) levels via blood tests can accurately predict which premenopausal women with hormone receptor-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy, potentially allowing about one in five patients to safely forgo cytotoxic treatment.
For decades, treating clinicians have relied heavily on chronological age and self-reported menstrual history to gauge menopausal status when deciding whether to recommend chemotherapy alongside endocrine therapy. However, these traditional metrics frequently lack biological precision. A research team has turned to a more direct marker of ovarian reserve—anti-Müllerian hormone—to fundamentally reshape how treatment decisions are tailored for patients enrolled in the phase III RxPONDER trial.
Ovarian Reserve as a Biological Compass for Chemotherapy
Published in the journal Annals of Oncology, the study evaluated blood samples taken from 1,556 women younger than 55 who participated in the broader RxPONDER trial. The original trial demonstrated that many premenopausal women benefited from chemotherapy while postmenopausal women generally did not. This new sub-analysis sought to uncover whether a blood-based biomarker could separate those with functioning ovarian reserves from those whose ovaries are already approaching natural menopause.
The laboratory evaluations were conducted at the Biomarker Discovery Laboratory at the University of Kansas Medical Center. Researchers utilized ultrasensitive assays capable of detecting extremely low concentrations of AMH and inhibin B (INHB) in the picograms per milliliter (pg/mL) range. The findings demonstrate that baseline serum levels of traditional reproductive hormones, including estradiol, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), were not associated with predictive potential for chemotherapy benefit. In contrast, AMH and ultrasensitive inhibin B independently predicted benefit.
In Plain English: The Clinical Takeaway
- Ovarian Reserve: This refers to the remaining capacity of the ovaries to produce eggs.
- Adjuvant Chemotherapy: Medications given after primary surgery to kill any remaining cancer cells and lower the statistical probability of disease recurrence.
- Hazard Ratio (HR): A statistical metric used in clinical trials to compare the risk of an event (such as cancer recurrence) occurring in one group versus a control group over time.
Clinical Outcomes Stratified by AMH Thresholds
The investigators established a clinical cutoff of 10 picograms per milliliter (pg/mL) to distinguish between normal and low ovarian reserve. Among the study cohort, 64% of patients presented with AMH levels at or above this 10 pg/mL threshold. In this subgroup, adding adjuvant chemotherapy to standard endocrine therapy reduced the risk of invasive disease recurrence by more than half, showing a hazard ratio of 0.46 with a 95% confidence interval ranging from 0.33 to 0.65 and an adjusted P-value of .00012.
On the other hand, no benefit regarding invasive disease-free survival was observed among the 36% of participants with diminished ovarian reserve—defined as an AMH level under 10 pg/mL—which resulted in an adjusted P-value of .47 and a hazard ratio of 1.27. A matching pattern emerged when evaluating distant relapse-free survival rates. Approximately one in five premenopausal women in the study displayed AMH levels low enough to indicate they could safely avoid the toxicity of chemotherapy.
| AMH Biomarker Status | Percentage of Cohort | Impact on Invasive Disease Recurrence | Statistical Significance (Adjusted P-Value) |
|---|---|---|---|
| Normal Reserve (≥10 pg/mL) | 64% | Reduced risk by more than half (HR = 0.46) | P = .00012 |
| Low Reserve (<10 pg/mL) | 36% | No significant improvement (HR = 1.27) | P = .47 |
Moving Toward Precision Oncology
The integration of AMH testing addresses a long-standing clinical dilemma in medical oncology. As noted by Andrew K. Direct measurement via ultrasensitive assays offers a more biologically meaningful assessment.
Accurately determining menopausal status is crucial for tailoring adjuvant chemotherapy regimens in hormone-positive breast cancer, as highlighted by study co-author Priyanka Sharma, M.D., a professor of medical oncology at KU Medical Center. Similarly, Kevin Kalinsky, M.D., professor and division director of medical oncology at Emory University School of Medicine and principal investigator of RxPONDER, noted that objective biological metrics will soon allow clinicians to move past age-based approximations and precisely identify patients who require cytotoxic intervention versus those who do not.
Contraindications & When to Consult a Doctor
Biomarker testing like AMH is designed as a specialized tool to assist medical oncologists in shared decision-making regarding adjuvant systemic therapy. It is not a standalone diagnostic test for detecting primary malignancy, nor does it replace comprehensive oncological evaluations or routine staging procedures. Patients with hormone receptor-positive, HER2-negative breast cancer should not alter prescribed endocrine therapy regimens or make independent treatment choices based solely on ovarian reserve assessments. Anyone experiencing new physical symptoms, unexpected side effects from therapy, or wishing to explore personalized recurrence risks should schedule an immediate consultation with their treating medical oncologist.
